CD137 Antibody (0.N.185): sc-70531

CD137 Antibody (0.N.185) is a mouse monoclonal IgG1 antibody that detects CD137 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD137, also known as ILA or 4-1BB in mouse, is a member of the tumor necrosis factor receptor family and plays a crucial role in the immune response by delivering a costimulatory signal to T lymphocytes. CD137 is primarily expressed on activated T cells and interacts with an inducible ligand found on B cells, macrophages, and dendritic cells, which is essential for effective antigen presentation and the generation of cytotoxic T cells. The structure of CD137 includes a cysteine-rich extracellular domain that is vital for ligand binding and subsequent signaling pathways, which ultimately influence T cell activation and survival. CD137 not only enhances immune responses but also regulates peripheral monocyte survival through the release of specific cytokines, including macrophage colony-stimulating factor. Soluble forms of CD137 have been identified in the sera of patients with rheumatoid arthritis, suggesting a potential role in modulating immune responses and providing insights into therapeutic strategies for autoimmune diseases. Anti-CD137 antibody (0.N.185) is an invaluable tool for researchers studying T cell biology and immune regulation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD137 Antibody (0.N.185) References:

1. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.  |  Milone, MC., et al. 2009. Mol Ther. 17: 1453-64. PMID: 19384291
2. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.  |  Chu, DT., et al. 2019. Int J Mol Sci. 20: PMID: 31013788
3. CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages.  |  Jiang, P., et al. 2019. Theranostics. 9: 2950-2966. PMID: 31244935
4. CD137, an attractive candidate for the immunotherapy of lung cancer.  |  Ye, L., et al. 2020. Cancer Sci. 111: 1461-1467. PMID: 32073704
5. CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases.  |  Wong, HY. and Schwarz, H. 2020. J Autoimmun. 112: 102499. PMID: 32505443
6. Contributions of Costimulatory Molecule CD137 in Endothelial Cells.  |  Yuan, W., et al. 2021. J Am Heart Assoc. 10: e020721. PMID: 34027676
7. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.  |  Liu, G. and Luo, P. 2023. Front Immunol. 14: 1208788. PMID: 37334375
8. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects.  |  Glez-Vaz, J., et al. 2023. Sci Adv. 9: eadf6692. PMID: 37595047
9. CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.  |  Tubridy, EA., et al. 2024. Gynecol Oncol. 184: 74-82. PMID: 38290413
10. CD137 (4-1BB) and T-Lymphocyte Exhaustion.  |  Molero-Glez, P., et al. 2024. Clin Cancer Res. 30: 3971-3973. PMID: 39120463

The preferred CD137 antibody is CD137 Antibody (BBK-2): sc-58947.